COPD describes a group of progressive lung diseases — primarily emphysema and chronic bronchitis — that obstruct airflow and make breathing difficult. The damage is permanent and cumulative.
By the time most patients are diagnosed, they have lost 30–50% of their lung function. The most common cause by a wide margin is cigarette smoking, but COPD also occurs in non-smokers from long-term exposure to indoor cooking smoke, occupational dust, or rare genetic conditions (alpha-1 antitrypsin deficiency).
Smokers susceptible to COPD lose lung function 2–4 times faster than non-smokers — and the decline curve returns to the normal aging slope as soon as the patient stops smoking, at any age. A 60-year-old who quits has 20+ years of FEV1 decline that looks like a healthy non-smoker's.
COPD describes a group of progressive lung diseases — primarily emphysema and chronic bronchitis — that obstruct airflow and make breathing difficult. The damage is permanent and cumulative. By the time most patients are diagnosed, they have lost 30–50% of their lung function. Roughly 16 million Americans have diagnosed COPD; the true number is higher, perhaps 24 million, because the disease often progresses for years before patients are tested. COPD is the fourth leading cause of death in the United States.
Early COPD often goes unrecognized. Patients attribute breathlessness to aging or being out of shape. By the time symptoms are obvious — daily cough with sputum, shortness of breath climbing a single flight of stairs, frequent winter infections — the disease is moderate-to-severe. A useful prompt: if you cannot walk and talk at the same time without becoming breathless, that is not normal at any age.
The diagnosis requires spirometry. We measure how much air you can blow out in one second (FEV1) after a bronchodilator. If your FEV1 divided by your total exhaled volume (FVC) is less than 0.70, you have airflow obstruction. We then stage severity (GOLD 1 through 4) based on the FEV1 percent predicted for your age, sex, and height. We also assess symptoms (mMRC or CAT score) and exacerbation history. The 2024 GOLD Report combines these into four groups (A, B, E) that guide treatment.
Smoking cessation is the single most important intervention, full stop. Nothing else slows decline as effectively. Inhaled bronchodilators (LAMA and LABA) are the foundation of maintenance therapy. Inhaled corticosteroids are added for patients with frequent exacerbations, especially with eosinophilic features. Pulmonary rehabilitation improves quality of life more than any single drug — yet less than 5% of eligible patients receive it. Vaccines (flu, pneumococcal, RSV, COVID) reduce exacerbations meaningfully. Oxygen for severe hypoxia improves survival. Lung volume reduction (surgical or via endobronchial valves) helps selected patients with severe emphysema.
This page is general medical information, not personalized medical advice. If you have questions about your specific health, talk with your Nimbus clinician.
